Autism research at the crossroads
By Brady Huggett,
Spectrum News
| 01. 25. 2023
In April of 2021, Emilie Wigdor finished up a paper titled “The female protective effect against autism spectrum disorder” and put it on the pre-print server medRxiv. Wigdor is a Ph.D. student in human genetics at the University of Cambridge and the Wellcome Sanger Institute in the United Kingdom, and the paper had taken three years to complete. It was also the first paper on which she was first author. She was proud of that, and she took to Twitter to promote the work in an 11-part thread.
Wigdor isn’t particularly active on the platform; she mostly retweets, and she has just hundreds of followers, many of whom are geneticists and researchers like her. A handful of them offered admiring comments in replies to her post. But when the paper was published in the peer-reviewed Cell Genomics in June 2022 and she put out a similar 11-tweet thread on 8 June, the response was quite different.
This time, one of the first replies was from an autistic researcher in Australia, who tagged Ann Memmott and pointed to Wigdor’s thread as...
Related Articles
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Stephanie Pappas, LiveScience | 01.15.2026
Genetic variants believed to cause blindness in nearly everyone who carries them actually lead to vision loss less than 30% of the time, new research finds.
The study challenges the concept of Mendelian diseases, or diseases and disorders attributed to...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...